EQRx, Inc. is a pharmaceutical firm dedicated to developing novel therapeutic agents. Its primary focus lies in creating treatments for oncological and immune-inflammatory disorders, with its operations primarily situated in the United States. The company's pipeline includes several key investigational drugs: Aumolertinib, an EGFR inhibitor designed for non-small cell lung cancer (NSCLC) patients with EGFR mutations; Sugemalimab, an anti-PD-L1 antibody targeting advanced (stage III and IV) NSCLC; Lerociclib, a CDK4/6 inhibitor for the treatment of HR+/HER2- breast cancer; and EQ176, an anti-PD-1 antibody currently under evaluation for liver cancer.